Dr. Soon-Shiong is hopeful the Saudi Arabian FDA's approval of his cancer therapy drug, Anktiva, will lead to widespread ...

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the disease.The ongoing SunRISe-3 trial (NCT05714202) is testing TAR-200 head-to-head ...

Armistice Capital acquired more shares of ImmunityBio as EMA recommended ANKTIVA approval and Q3 2025 product revenue surged ...

ImmunityBio (IBRX) shares added ~12% in the premarket on Wednesday after the Saudi Food and Drug Authority approved its ...

Immunotherapy uses the power of your immune system to fight your cancer. One type of immunotherapy is called an immune checkpoint inhibitor. Your immune system has built-in checkpoints that help it ...

CG Oncology has announced that topline data from its Phase 3 PIVOT-006 trial of intravesical cretostimogene grenadenorepvec ...

BERLIN October 20, 2025 – Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the cancer benefit from immunotherapy with atezolizumab ...

Invasive bladder cancer can be treated through immunotherapy involving Bacillus Calmette-Guérin (BCG), but some 40%-60% of treated patients suffer progression or recurrence. In an effort to find more ...

Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.